Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Justin Stebbing
AddedMar 31, 2024
UpdatedMay 31, 2026
Justin Stebbing

Justin Stebbing

Board Member, NightHawk Biosciences

CrunchbaseLinkedIn

Justin Stebbing's Career

NightHawk Biosciences
NightHawk Biosciences

Morrisville, NC, US

Board Member· Board
Zephyr AI
Zephyr AI

Dallas, TX, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Justin Stebbing's Career

NightHawk Biosciences
NightHawk Biosciences
Public$59.3M772008Morrisville, NC, US
Board Member· Board

Leadership at NightHawk Biosciences

John MonahanJohn MonahanBoard Member
Jeff WolfJeff WolfBoard Member
John PrendergastJohn PrendergastBoard Member
Edward B. Smith IIIEdward B. Smith IIIBoard Member
Zephyr AI
Zephyr AI
Seed$18.5M472020Dallas, TX, US
Board Member· Board

Leadership at Zephyr AI

Yisroel BrumerYisroel BrumerBoard Member
David L. Morgan IIDavid L. Morgan IICEO
Grant VerstandigGrant VerstandigBoard Member

Similar to Zephyr AI

BioAI HealthBioAI HealthGoffstown, NH, USAI Diagnostics, Biotechest. 2020BioAI HealthGoffstown, NH, US · est. 2020

BioAI Health: Leveraging AI for improved disease diagnosis, therapy response prediction, and clinical trials.

Seed · $3M9
Pathos AIPathos AIChicago, IL, USDrug Discoveryest. 2020Pathos AIChicago, IL, US · est. 2020

Pathos: AI and big data-driven platform streamlining end-to-end drug discovery and development.

Series B · $20M3
InsitroInsitroSouth San Francisco, CA, USDrug Discoveryest. 2018InsitroSouth San Francisco, CA, US · est. 2018

Insitro: Leveraging machine learning for data-driven drug discovery and development.

Series C · $643M295
TandemAITandemAINew York City, NY, USDrug Discoveryest. 2021TandemAINew York City, NY, US · est. 2021

TandemAI: An advanced AI company revolutionizing drug discovery.

Series A · $60M46

Justin Stebbing's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Justin Stebbing

Ethan BernsteinEthan BernsteinBoard Member · Protocol LabsBrian JohnstonBrian JohnstonBoard Member · RealSeq BiosciencesMichael SerioMichael SerioBoard Member · Image InsightJustin SwaneyJustin SwaneyCo-Founder · SamplyJason EriksenJason EriksenBoard Member · Alzeca BiosciencesRoberto De PontiRoberto De PontiBoard Member · OncoResponse